How big is the Hodgkin's lymphoma market | Value, Segments & Trends 2025

Q: What is the current size of the Hodgkin's lymphoma market?

The Hodgkin's lymphoma market was valued at USD 1.4 billion in 2024 and is expected to reach USD 2.3 billion by 2031.

Q: What is the CAGR of the Hodgkin's lymphoma market?

The Hodgkin's lymphoma market is growing at a CAGR of 7.3% during 2025–2031.

Q: What’s driving growth in the Hodgkin's lymphoma market?

Increased use of immunotherapy, improved diagnostics, and global awareness.

Q: What are the key treatments available in the Hodgkin's lymphoma market?

Chemotherapy, radiation therapy, immunotherapy, and stem cell transplant.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6242

Publication Date: Jul 2025

How big is the Hodgkin's Lymphoma Market?

According to 6Wresearch internal database and industry insights, the Hodgkin's lymphoma market was valued at approximately USD 1.4 billion in 2024 and is projected to reach USD 2.3 billion by 2031, growing at CAGR of 7.3% during the forecast period.

The market is expanding steadily due to rising awareness, improved diagnostics, and new immunotherapy and targeted drug developments.

Key Growth Drivers of the Hodgkin's Lymphoma Market

The rise in the cases of Hodgkin lymphoma across the world
Immunotherapy and targeted treatments developments
Cancer awareness activities and government programs
Increase access to healthcare in the developing areas
Improved diagnostic equipment, which makes it possible to detect the disease at an early age

Hodgkin's Lymphoma Market Trends

The Hodgkin's lymphoma market is undergoing significant transformation due to the emergence of advanced treatment modalities and changing clinical approaches. Checkpoint inhibitors, such as PD-1/PD-L1 blockers, have shifted the treatment landscape by offering better outcomes for relapsed or refractory cases. CAR-T cell therapies are entering clinical trials for Hodgkin’s lymphoma, showing promising results in targeting CD30-positive malignancies. There is also an increasing focus on personalized and precision medicine, where genetic and molecular profiling helps oncologists determine the most effective treatment plan. The use of biomarkers is becoming more common to predict response to therapies.

Emerging Developments in the Hodgkin's Lymphoma Market

The Hodgkin’s lymphoma market dynamics are currently centered on the improvement of therapeutic effect and reduction of the level of toxicity in Hodgkin lymphoma disease. Among the most promising, the areas of development of CAR-T cell therapies that target only the CD30 antigens are common in Hodgkin lymphoma. The therapies are under phase I and II clinical trials and thus can be used as an alternative to relapsed or refractory cases that cannot be treated with conventional therapies. A third important trend is the use of next-generation sequencing (NGS) and liquid biopsy technologies that will allow monitoring the progression of the disease and response to treatments in real-time.